Beilloso Facial Bump Refining Essence

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the improvement of skin texture through gentle exfoliation. It is designed to aid in the smoothing of the skin, making it suitable for individuals seeking to enhance the overall appearance and feel of their skin.

Dosage and Administration

Healthcare professionals are advised to instruct patients to apply the product daily after cleansing and toning the skin. For optimal results, the product should be used twice a day for a minimum duration of 4 weeks.

A pea-sized amount of the essence should be dispensed onto the affected area. Patients should use their fingertips to gently massage the essence into the skin until it is fully absorbed. Continued use is recommended until the appearance of skin papules is resolved and does not recur.

Contraindications

Use is contraindicated in the following situations:

Children under 2 years of age should not be treated with this product due to the potential for adverse effects. Additionally, application on open skin wounds is contraindicated to prevent the risk of infection and other complications.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients to discontinue use and seek medical attention if any rash or irritation develops. It is crucial to monitor for signs of irritation or rash during treatment, as these may indicate an adverse reaction.

In the event of accidental ingestion, immediate medical assistance should be sought. Patients should be instructed to contact the Poison Control Center without delay to ensure appropriate management and care.

Side Effects

Patients using this product should be aware that it is intended for external use only. In the event of rash or irritation, it is advised to discontinue use and consult a healthcare professional. This recommendation is reinforced by clinical observations, which indicate that irritation or rash may occur in some individuals. Therefore, patients are encouraged to monitor their skin condition closely while using the product and to seek medical advice if any adverse reactions arise.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Beilloso Facial Bump Refining Essence (salicylic acid 1% facial bump refining essence). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 2 years of age should not use this medication. It is important to keep the product out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

There is no information available regarding the use of Beilloso Facial Bump Refining Essence during pregnancy. As such, safety concerns, dosage modifications, or special precautions for pregnant patients have not been established. Healthcare professionals should exercise caution when considering the use of this product in women of childbearing potential and discuss potential risks with their patients.

Lactation

There are no specific warnings or recommendations regarding the use of this product by lactating mothers. Additionally, there is no information available about the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

There is no specific information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary depending on the substance involved and the individual patient’s characteristics. Symptoms of overdose can range from mild to severe and may include altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate medical evaluation is recommended. Healthcare professionals should assess the patient's vital signs and conduct a thorough clinical examination. Supportive care should be initiated as necessary, which may include airway management, intravenous fluids, and monitoring of vital parameters.

If specific antidotes or treatments are available for the substance involved, they should be administered according to established protocols. Consultation with a poison control center or toxicology expert may also be warranted to guide management decisions.

It is crucial to document all findings and interventions in the patient's medical record and to report any adverse events to the appropriate regulatory authorities as required.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children. In the event of accidental ingestion, patients should seek medical assistance or contact the Poison Control Center immediately.

It is important to inform patients that this medication is not recommended for use in children under 2 years of age or on open skin wounds. Patients should be instructed to discontinue use and consult a healthcare professional if they experience any irritation or rash.

While using the medication, patients should be cautioned to avoid contact with the eyes, ears, mouth, and any open or broken skin areas. In the case of accidental contact with the eyes, patients should rinse their eyes thoroughly with water.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product in a cool, shady place to maintain its integrity and effectiveness. Proper storage conditions are crucial to ensure the product remains within the recommended temperature range and is protected from direct sunlight and excessive heat.

Additional Clinical Information

The product is administered topically, with a recommended application of once daily after cleansing and toning, or twice a day for a minimum of four weeks. Clinicians should counsel patients that the product is for external use only. Patients are advised to discontinue use and consult a doctor if a rash or irritation occurs. In case of contact with eyes, thorough rinsing with water is necessary. The product should be kept out of reach of children, and if ingested, medical assistance or contact with the Poison Control Center is required.

No additional information is available regarding laboratory tests, abuse potential, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Beilloso Facial Bump Refining Essence, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)